Intent to Announce - RPP17-01 of MCDC OTA

This is not a Request for Prototype Proposals, but for planning purposes only. A project award will not be awarded from this announcement. The Government intends to announce two Request for Prototype Proposals (RPP17-01 & RPP 17-02) for execution of a project award(s) in support of Medical Countermeasure Systems Research and Development related to specified project requirements. The purpose of this announcement is to provide members of the Medical CBRN Defense Consortium, and industry in general, advanced notification of Government intent. On 08 April 2016, the Government entered into an Other Transaction Agreement (OTA) with one (1) consortium, the Medical CBRN Defense Consortium (MCDC), in support of Medical Countermeasure Systems related research and development prototype projects. It is the intent of the Government to make project award(s) to member(s) of the MCDC as a result of member project proposals submitted via the Request for Prototype Proposals process. The Government anticipates two (2) projects for white papers and full proposals to be solicited via W15QKN-16-9-1002 - consisting of the following: 1. Development of an FDA-approved countermeasure that demonstrates non-GLP in vivo activity and potential efficacy consistent with the product's intended use in a suitable animal model target at one of the following (Treatment sub-objective): o Bacillus anthracis (Anthrax) o Brucella spp. (Brucellosis) o Burkholderia mallei (Glanders) o Burkholderia pseudomallei (Meliodosis) o Francissila tularensis (Tularemia) o Yersinia pestis (Plague) 2. Development of an FDA-approved antiviral medical countermeasure (MCM) that is efficacious against at least one of the viruses in the following families (Treatment sub-objective): o Filoviridae (Zaire ebolavirus, Sudan ebolavirus, Marburg marburgvirus, Tai Forest, and Bundibugyo) o Alphaviridae (Eastern Equine Encephalitis, Western Equine Encephalitis, Venezuelan Equine Encephalitis); Bunyaviridae (Hantan) The Government also anticipates four (4) projects for full proposal only (no white papers expected) to be solicited via W15QKN-16-9-1002 - consisting of the following: 1. Development of Marburg Vaccine Prototype Against Aerosolized Marburg Virus: (Prevention sub-objective) 2. Development of an multiple-target single-vector Vaccine Prototype Against Aerosolized Equine Encephalitic viruses including Venezuelan Equine Encephalitis Virus (Prevention sub-objective) 3. Development of a lightweight, low complexity device that diagnoses pathogenic biological weapon agents and regional infectious diseases in syndromic, multiplexed assay panels (Detection sub-objective) 4.Development of Sudan Ebolavirus (SUDV) Vaccine Prototype against aerosolized SUDV (Prevention sub-objective) The MCDC will host a webinar on January 10, 2017 from 2-4pm to provide an opportunity for all interested parties to gain additional information regarding the Government's objectives. Specific details regarding the webinar instruction can be obtained by contacting MCDC. In order to respond to MCDC requests regarding the above projects, you must be a member of the Medical CBRN Defense Consortium (MCDC), http://ncbdconsortium.org. For more information regarding membership or general questions to the MCDC, contact Michael Stebbins, at 843-760-4094 or mcdc@ati.org.